Transarterial chemoembolization in patients with hepatocellular carcinoma: Predictors of survival

Canadian Journal of Gastroenterology

Volumn 25, Issue 8, 2011, Pages 426-432

  Sawhney, Summit ^a   Montano Loza, Aldo J ^b   Salat, Peter ^a   McCarthy, Mairin ^a   Kneteman, Norman ^b   Meza Junco, Judith ^c   Owen, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

Hepatocellular carcinoma; Survival; Transarterial chemoembolization; Tumour size

Indexed keywords

ALPHA FETOPROTEIN; CEFAZOLIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; METRONIDAZOLE; MITOMYCIN; ONDANSETRON;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER MORTALITY; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; HOSPITALIZATION; LIVER TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053313017     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/864234     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6. (Pubitemid 32911406)
2. Mazzaferro V, Regalio E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
3. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;6:1394-403. (Pubitemid 32496976)
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
5. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. (Pubitemid 34454013)
6. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication 48. Geneva: World Health Organization, 1979.
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
11. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9.
12. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
13. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008;14:1107-15.
14. Heinze G, Gnant M, Schemper M. Exact log-rank tests for unequal follow-up. Biometrics 2003;59:1151-7. (Pubitemid 38021246)
15. Cox DR. Regression models and life tables (with discussion). JR Stat Soc B 1972;34:187-220.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36. (Pubitemid 12142173)
17. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989;97:965-71. (Pubitemid 19239037)
18. Chang JM, Tzeng WS, Pan HB, et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 1994;74:2449-53.
19. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994;74:16-24. (Pubitemid 24187604)
20. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995;75:2427-34.
21. Hatanaka Y, Yamashita Y, Takaha, et al. Unresectable hepatocellular carcinoma: Analysis of prognostic factors in transcatheter management. Radiology 1995;195:747-52.
22. Chung JM, Park JH, Han JK, et al. Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40.
23. Solomon B, Soulen MC, Baum RA, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: Prospective evaluation of response and survival in a US population. J Vasc Interv Radiol 1999;10:793-8. (Pubitemid 29284310)
24. Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: Analysis of factors affecting local recurrence and survival rates. Am J Roentgenol 2001;176:681-8. (Pubitemid 32181966)
25. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009;115:616-23.
26. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
27. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832-8.
28. Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: Oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-42.